Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

University of Minnesota, 2020 NCT04312009

losartan (n=101) vs. placebo (n=104)

randomized controlled trial   some concerns about risk of bias

Studied treatment

losartan for 7 days or hospital discharge
Losartan 50 mg PO twice daily (100 mg daily total) administered for 10 days.

Control treatment

placebo for 7 days or hospital discharge
placebo (microcrystalline methylcellulose, gelatin capsule); oral administration

Patients

COVID 19 all comers

18 years and older with presumptive positive laboratory test for SARS-coV-2 or upper respiratory infection with recent exposure to laboratory-proven SARS-coV-2-infected person�negative influenza and respiratory virus panel�new or worsening hypoxia (spO2 <95%) compared to baseline or increasing oxygen requirement�randomization within 24 hours of initial presentation to a hospital (inclusive of transfer)exclusion criteria:�currently taking an angiotensin converting enzyme inhibitor (ACei) or angiotensin receptor blocker (ARB)�prior reaction or intolerance to an ARB or ACei

Method

Double-blind.

Multi-center: 13 hospitals in the United States.

Participants discharged prior to day 7 were provided a home pulse oximeter and contacted via phone.

Remark